FDA's failure to inspect a Chinese API manufacturer that may be linked to the heparin safety issue will "drive home" to the pharmaceutical industry the need to ensure the safety of the ingredients in drug products, according to an industry expert
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Lynkuet will compete with Astellas's Veozah/Veoza
The list of small-cap companies with the fastest-rising share prices so far this year is dominated by Chinese companies, underscoring their growing contribution to the global biopharma ecosystem.
Soleno Therapeutics will raise about $200m gross proceeds from an offering of 2.35m of its common stock to fund the commercialization of Vykat XR, which became the first drug for Prader-Willi syndrome to gain US approval on March 26.
